Pfizer stock offers 30% upside with strong non-COVID franchises, margin expansion, and pipeline potential. Click here to read ...

Pfizer's coronavirus vaccine could face some headwinds in the near future. The company will enter a period of patent cliffs ...

Pfizer (NYSE: PFE) and Teva Pharmaceutical Industries (NYSE: TEVA) just reported third-quarter earnings that reveal two ...

Mounjaro and Pfizer’s ($PFE) cancer drugs were added to China’s state-run health insurance scheme, according to the country’s ...

Pfizer has unveiled phase 3 results that could help the company’s hemophilia drug Hympavzi level the playing field in its ...

These three drugmakers are all well off their recent highs. Is this a sign of opportunity or risk?

3SBio, a China partner of U.S. drug giant Pfizer, has reached agreements to raise approximately $400 million in a share ...

Eli Lilly & Co., Pfizer Inc. and Johnson & Johnson secured spots on China’s first innovative drug catalog, opening a new ...

A Pfizer-backed biotech landed $120M, embattled Kala Bio has secured a new CEO, and Akebia Therapeutics bought a rare kidney ...

Pfizer is launching seven phase 3 studies for PF-4044 soon and plans to initiate an additional 10 (at least) by the end of ...

Some experts cited the case of Slentrol, an older weight loss drug for dogs made by Pfizer’s animal health division (which ...

Three years after introducing Hemgenix, the first gene therapy for hemophilia B, CSL Behring has released long-term data ...